Abstract
Within the context of this section, biomarkers are defined as a panel of proteins and peptides that are predictive of the risk for developing a pathological condition. It is important to note here that the use of the descriptor ‘panel’ is purposeful in that single “biomarkers” are rarely sufficient to permit accurate prediction of a pathological condition. More specifically, the primary application of a biomarker panel is that it serves as a molecular indicator of the severity of a disease or its early response to treatment. In this way, biomarkers enable the application of precision medicine, an approach that tailors specific interventions to those individuals that would most benefit. For a recent comprehensive review of the proteomic-based biomarker development process with a focus on bladder cancer, the reader is directed to Frantzi et al. [Clin Transl Med 3:7, 2014], or a special issue with multiple reviews [Stuhler and Poschmann, Biochim Biophys Acta Proteins Proteomics 1844:859–1058, Elsevier, B V, 2014].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frantzi M, Bhat A, Latosinska A (2014) Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 3:7
Stuhler K, Poschmann G (2014) Biomarkers: a proteomic challenge. Biochim Biophys Acta Proteins Proteomics 1844:859–1058, Elsevier, B V
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983
World Health, O (2009) Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, Geneva
ad-hoc writing committee of the Assembly on Allergy, I. a. I (2000) Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 162:2341–2351
Sun W, Hu G, Long G, Wang J, Liu D, Hu G (2014) Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Curr Med Res Opin 30:2033–2039
Li X-j, Hayward C, Fong P-Y, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, Gingras O, Lamontagne J, Allard R, Chelsky D, Price ND, Lam S, Massion PP, Pass H, Rom WN, Vachani A, Fang KC, Hood L, Kearney P (2013) A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 5:207ra142
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wiktorowicz, J.E., Brasier, A.R. (2016). Introduction to Clinical Proteomics. In: Mirzaei, H., Carrasco, M. (eds) Modern Proteomics – Sample Preparation, Analysis and Practical Applications. Advances in Experimental Medicine and Biology, vol 919. Springer, Cham. https://doi.org/10.1007/978-3-319-41448-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-41448-5_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41446-1
Online ISBN: 978-3-319-41448-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)